Status:
UNKNOWN
Clinical Usefulness and Prognostic Significance of Interim 18F-FDG PET/CT for the Treatment of Peripheral T Cell Lymphomas
Lead Sponsor:
Chonnam National University Hospital
Collaborating Sponsors:
Kyungpook National University Hospital
Conditions:
Peripheral T Cell Lymphoma
Eligibility:
All Genders
18+ years
Brief Summary
Although interim 18F-fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET)/computerized tomography (CT) scan has emerged as a powerful prognostic tool in predicting treatment outcome in Hodg...
Detailed Description
1. Treatment protocol * Patients with limited-stage (stage I/II) are treated with CHOP/CHOP-like chemotherapy \[cyclophosphamide 750 mg/m2 i.v. on D1, vincristine 1.4 mg/m2 i.v. on D1, doxorubicin...
Eligibility Criteria
Inclusion
- Age above 18 years
- Histologically proven PTCLs except primary cutaneous/subcutaneous panniculitis
- ECOG performance status ≤ 2
- Patients who are available to be performed PET/CT at diagnosis
- No severe concomitant disease
Exclusion
- Patients who did not undergo PET/CT scans at diagnosis
- Patients who have a primary CNS lymphoma
- Patients who have a HIV or HTLV-1
- Patients who could not receive primary chemotherapy
Key Trial Info
Start Date :
August 1 2004
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 1 2012
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT01470066
Start Date
August 1 2004
End Date
May 1 2012
Last Update
November 11 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chonnam National University Hwasun Hospital
Hwasun-gun, Jeollanam-do, South Korea, 519-809